BioScrip, Inc. (BIOS) Upgraded to Buy at SunTrust Banks, Inc.

BioScrip, Inc. (NASDAQ:BIOS) was upgraded by equities research analysts at SunTrust Banks, Inc. from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Marketbeat reports. The brokerage presently has a $3.75 price objective on the stock, up from their previous price objective of $3.25. SunTrust Banks, Inc.’s target price suggests a potential upside of 29.76% from the stock’s current price.

Other analysts have also issued reports about the company. Barrington Research boosted their target price on BioScrip to $3.50 and gave the company an “outperform” rating in a research report on Monday, June 26th. BidaskClub lowered BioScrip from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 1st. Zacks Investment Research raised BioScrip from a “sell” rating to a “hold” rating in a research report on Wednesday, June 28th. ValuEngine lowered BioScrip from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $4.00 target price (up from $3.00) on shares of BioScrip in a research report on Thursday. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. BioScrip has a consensus rating of “Buy” and a consensus price target of $3.75.

BioScrip (NASDAQ:BIOS) traded up 8.65% during midday trading on Thursday, reaching $3.14. The company had a trading volume of 782,444 shares. BioScrip has a 12-month low of $0.98 and a 12-month high of $3.43. The company’s market capitalization is $400.16 million. The stock has a 50-day moving average price of $2.81 and a 200 day moving average price of $2.01.

BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by $0.01. The firm had revenue of $218.11 million during the quarter, compared to analysts’ expectations of $220.05 million. During the same period in the previous year, the business posted ($0.14) earnings per share. The company’s quarterly revenue was down 6.2% on a year-over-year basis. Equities analysts forecast that BioScrip will post ($0.38) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “BioScrip, Inc. (BIOS) Upgraded to Buy at SunTrust Banks, Inc.” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://sportsperspectives.com/2017/08/10/bioscrip-inc-bios-upgraded-to-buy-at-suntrust-banks-inc.html.

A number of institutional investors have recently added to or reduced their stakes in the stock. Gilder Gagnon Howe & Co. LLC increased its position in BioScrip by 248.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 15,211,136 shares of the company’s stock worth $41,298,000 after buying an additional 10,845,410 shares during the period. FMR LLC increased its position in BioScrip by 3,489.1% in the fourth quarter. FMR LLC now owns 3,529,795 shares of the company’s stock worth $3,671,000 after buying an additional 3,431,447 shares during the period. California Public Employees Retirement System increased its position in BioScrip by 37.5% in the first quarter. California Public Employees Retirement System now owns 663,700 shares of the company’s stock worth $1,128,000 after buying an additional 181,000 shares during the period. Roanoke Asset Management Corp NY increased its position in BioScrip by 72.9% in the second quarter. Roanoke Asset Management Corp NY now owns 403,280 shares of the company’s stock worth $1,095,000 after buying an additional 170,000 shares during the period. Finally, Benchmark Capital Advisors bought a new position in BioScrip during the second quarter worth about $391,000. Institutional investors and hedge funds own 91.16% of the company’s stock.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply